ResMed Inc. (RMD) Institutional Ownership & Insider Trading

883 institutions reported holding ResMed Inc. shares in 13F filings for the quarter ended 2026-06-30, according to EquiReason's reading of their SEC filings. 34 insider trades on Form 4 since 2025-10-01.

Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason

RMDResMed Inc.Follow RMD — free

Medical Instruments & Supplies · Healthcare

—

Price chart with a free account

Market cap: 36.5B
P/E TTM: 24.2
Dividend yield: 0.9%
52-week: —
Next earnings: 29 Oct, in 5 days

Institutions · all 13F filers

quarter to 30 Jun 2026 · filers in both quarters

883 institutions held 69.3% of the shares. Across filers that reported both quarters, shares held changed +1.9%.

Largest moves, shares (millions)

Institutional flow by quarter

net shares added or trimmed, millions · filers in both quarters

Quarter	Holders	Shares held, M	Change	Increased	New	Decreased	Closed
Jun 26	883	100	+1.9%	281	65	314	116
Mar 26	930	97	+1.3%	317	67	284	66
Dec 25	928	96	+3.0%	284	51	297	79
Sep 25	923	92	+0.6%	295	78	273	57
Jun 25	904	92	-2.5%	291	89	283	53
Mar 25	856	92	+3.1%	297	75	241	63
Dec 24	845	90	+2.4%	288	82	213	48
Sep 24	781	86	-3.8%	276	80	216	55

ResMed Inc. — questions

Who owns ResMed Inc. stock?: 883 institutions reported ResMed Inc. shares in 13F filings for the quarter ended 2026-06-30. The largest: BlackRock, Inc. (8.5%), VANGUARD CAPITAL MANAGEMENT LLC (6.6%), VANGUARD PORTFOLIO MANAGEMENT LLC (5.5%).
Are ResMed Inc. insiders buying or selling?: 34 insider trades on Form 4 since 2025-10-01; the full list, with dates, people and plan status, is on this page.

Every figure on this page comes from ResMed Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.

How these figures are read: methodology · EquiReason.

Important information. Figures on this page are taken from filings submitted to the U.S. Securities and Exchange Commission (SEC) and processed automatically by EquiReason. They may contain errors, omissions or delays, and EquiReason makes no representation or warranty as to their accuracy, completeness or timeliness. Always verify figures against the original filing on SEC EDGAR before relying on them.

This page is provided for general information and educational purposes only. It does not constitute investment, financial, legal or tax advice, and it is not a recommendation or an offer to buy, sell or hold any security. It does not take into account your objectives, financial situation or needs. Past performance does not guarantee future results; any reliance on this information is at your own risk. See our Disclaimer and Risk Disclosure.